Oxford Biomedica PLC Extension of Commercial Supply Agreement (4052X)
December 19 2019 - 2:00AM
UK Regulatory
TIDMOXB
RNS Number : 4052X
Oxford Biomedica PLC
19 December 2019
The information contained within this announcement is deemed by
the Company to constitute inside information as stipulated under
the Market Abuse Regulation (EU) No. 596/2014. Upon the publication
of this announcement via the Regulatory Information Service, this
inside information is now considered to be in the public
domain.
Oxford Biomedica Extends Commercial Supply Agreement by Five
Years for Manufacture of Lentiviral Vectors
Oxford, UK - 19 December 2019: Oxford Biomedica plc (LSE:OXB)
("Oxford Biomedica" or "the Group"), a leading gene and cell
therapy group, announced today that it has extended its commercial
supply agreement with Novartis for the manufacture of lentiviral
vectors for the Novartis CAR-T portfolio including five lentiviral
vectors for CAR-T products. This builds on the existing three year
commercial supply agreement signed by the parties in July 2017.
Under the terms of the Agreement, Oxford Biomedica will receive
a minimum $75 million from Novartis over the next five years in
manufacturing revenue with additional undisclosed process
development fees. A mid single digit GBPm payment will also be paid
in the medium term as a facility reservation fee with other terms
such as royalties on net sales of resulting CAR-T products as
previously agreed in 2014.
Oxford Biomedica will dedicate a manufacturing facility to
Novartis within its new 7,800m(2) commercial manufacturing centre
OxBox, in Oxford, UK. Oxford Biomedica will also be responsible for
ensuring that at least two of its GMP facilities are capable of
commercial supply for Novartis' CAR-T progammes.
John Dawson, Chief Executive Officer of Oxford Biomedica, said:
"This five year extension to our commercial supply agreement with
Novartis for the LentiVector(R) platform is testament to the joint
success achieved in this strategically important collaboration
since 2013. This closely integrated collaboration with Novartis
underlines the long-term committment both companies have made to
manufacturing CAR-T therapies.
"This is also the first long-term commitment of a partner to
reserve a dedicated GMP facility in our new OxBox GMP facility,
which we expect to become operational in early 2020. While stable
and long-term supply of lentiviral vectors for commercial CAR-T
products is key to both companies, we are also pleased to announce
that we are now working on five different lentiviral vectors for
CAR-T products in the Novartis portfolio and we look forward to
helping Novartis to innovate in this exciting therapeutic
space".
-Ends-
Enquiries:
Oxford Biomedica plc T: +44 (0)1865 783 000
John Dawson, Chief Executive Officer T: +44 (0)1865 783 000
Stuart Paynter, Chief Financial Officer T: +44 (0)1865 954 161 / E: ir@oxb.com
Catherine Isted, Head of Corporate
Development & IR
T: +44 (0)20 3709 5700
Consilium Strategic Communications
Mary-Jane Elliott/Matthew Neal
About Oxford Biomedica
Oxford Biomedica (LSE:OXB) is a leading, fully integrated, gene
and cell therapy group focused on developing life changing
treatments for serious diseases. Oxford Biomedica and its
subsidiaries (the "Group") have built a sector leading lentiviral
vector delivery platform (LentiVector(R) ), which the Group
leverages to develop in vivo and ex vivo products both in-house and
with partners. The Group has created a valuable proprietary
portfolio of gene and cell therapy product candidates in the areas
of oncology, ophthalmology, CNS disorders, liver diseases and
respiratory disease. The Group has also entered into a number of
partnerships, including with Novartis, Sanofi, Axovant Gene
Therapies, Orchard Therapeutics, Santen, Boehringer Ingelheim, the
UK Cystic Fibrosis Gene Therapy Consortium and Imperial
Innovations, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford Biomedica is
based across several locations in Oxfordshire, UK and employs more
than 480 people. Further information is available at
www.oxb.com
About OxBox
OxBox is Oxford Biomedica's new 7,800 m(2) commercial
manufacturing centre, located in Oxford, UK. Phase I, which will be
operational in 2020, is 4,200 m(2) of developed area consisting of
six GMP clean room suites - four for vector production and two for
fill-finish, warehousing and cold chain facilities and support
laboratories. Phase II will provide for flexible expansion for a
further six GMP clean room suites. This world class facility is
expected to more than double Oxford Biomedica's manufacturing
capacity, supporting further growth in revenues.
The person who arranged for the release of this announcement on
behalf of Oxford Biomedica plc was John Dawson, Chief Executive
Officer.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCTPBTTMBIBTML
(END) Dow Jones Newswires
December 19, 2019 02:00 ET (07:00 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024